ENGLEWOOD CLIFFS, NJ, April 19, 2023 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq:SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has commenced development of a novel formulation as a targeted prophylactic treatment, designated as SPC-15, intended for stress, anxiety, and PTSD.


Previous articleBright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202
Next articlePsychedelics Weekly – The Church of Psilomethoxin Controversy, Psychedelics for Long COVID, and The Growth of Bicycle Day